Pfizer wins bid to invalidate 2 GSK patents relating to RSV vaccine Ruchika Sharma9 Oct 2024 2:33 PM ISTLondon: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held by GlaxoSmithKline (GSK)...
Moderna forecasts lower sales next year, shares near four-year low MD Bureau Team14 Sept 2024 11:34 AM ISTLondon: Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted...
New RSV vaccine can result in individual and societal cost savings, benefits for elderly: Study Dr. Kamal Kant Kohli6 Sept 2024 8:30 PM ISTVaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of...
New JAMA study backs RSV vaccine safety during pregnancy Dr. Kamal Kant Kohli10 July 2024 4:00 AM ISTVaccinating mothers against respiratory syncytial virus (RSV) during late pregnancy to protect their newborns is not associated with an increased risk...
USFDA approves expanded age indication for GSK RSV vaccine Arexvy for adults aged 50-59 at increased risk Ruchika Sharma9 Jun 2024 10:00 AM ISTLondon: GSK plc has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine,...
Moderna gets USFDA nod for mRNA RSV vaccine Ruchika Sharma2 Jun 2024 1:30 PM ISTCambridge: Moderna, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory...
Modify CT Protocol: CDSCO Panel Tells GSK on Respiratory Syncytial Virus(RSV) Vaccine Dr. Divya Colin24 March 2024 6:00 PM ISTNew Delhi: Reviewing the Phase III clinical trial protocol presented by the drug major GSK for the Respiratory Syncytial Virus (RSV) vaccine...
RSV vaccine Abrysvo is protective through a second year: Pfizer Ruchika Sharma3 March 2024 12:00 PM ISTNew York: Pfizer has said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the...
GSK vaccine Arexvy accepted for regulatory review by EMA for adults aged 50-59 at increased risk for RSV Ruchika Sharma4 Feb 2024 10:00 AM ISTLondon: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to expand the use of its...
Moderna jumps on Oppenheimer upgrade, 2025 sales growth goal Ruchika Sharma3 Jan 2024 9:00 AM ISTAccording to Oppenheimer, Moderna could have five products on the market by 2026.
Pfizer maternal vaccine Abrysvo bags USFDA approval for RSV prevention in infants Ruchika Sharma22 Aug 2023 11:26 AM ISTNew York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO (Respiratory Syncytial Virus Vaccine),...
Pfizer sued by GSK for patent infringement over RSV vaccine Ruchika Sharma3 Aug 2023 12:30 PM ISTA GSK spokesperson said in a statement that intellectual property protections are the "foundation of research-based companies' ability to drive...
